WO1993009222A3 - Transfection of vertebrate cells e.g. by homologous recombination - Google Patents
Transfection of vertebrate cells e.g. by homologous recombination Download PDFInfo
- Publication number
- WO1993009222A3 WO1993009222A3 PCT/US1992/009627 US9209627W WO9309222A3 WO 1993009222 A3 WO1993009222 A3 WO 1993009222A3 US 9209627 W US9209627 W US 9209627W WO 9309222 A3 WO9309222 A3 WO 9309222A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- product
- transfected
- primary
- dna
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormones [GH] (Somatotropin)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU30698/92A AU669499B2 (en) | 1991-11-05 | 1992-11-05 | Transfection of vertebrate cells e.g. by homologous recombination |
DE69221168T DE69221168T2 (en) | 1991-11-05 | 1992-11-05 | TRANSFECTION OF VERTEBRATE CELLS FOR EXAMPLE BY HOMOLOGOUS RECOMBINATION |
CA002122991A CA2122991A1 (en) | 1991-11-05 | 1992-11-05 | Transfection of vertebrate cells by homologous recombination |
JP50876793A JP3564126B2 (en) | 1991-11-05 | 1992-11-05 | Transfection of vertebrate cells by homologous recombination |
EP92924367A EP0649464B1 (en) | 1991-11-05 | 1992-11-05 | Transfection of vertebrate cells e.g. by homologous recombination |
GR970402700T GR3025054T3 (en) | 1991-11-05 | 1997-10-15 | Transfection of vertebrate cells e.g. by homologous recombination. |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78784091A | 1991-11-05 | 1991-11-05 | |
US78918891A | 1991-11-05 | 1991-11-05 | |
US787,840 | 1991-11-05 | ||
US789,188 | 1991-11-05 | ||
US91153392A | 1992-07-10 | 1992-07-10 | |
US911,533 | 1992-07-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1993009222A2 WO1993009222A2 (en) | 1993-05-13 |
WO1993009222A3 true WO1993009222A3 (en) | 1993-10-28 |
Family
ID=27419842
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1992/009627 WO1993009222A2 (en) | 1991-11-05 | 1992-11-05 | Transfection of vertebrate cells e.g. by homologous recombination |
Country Status (19)
Country | Link |
---|---|
US (7) | US5994127A (en) |
EP (3) | EP1221477A3 (en) |
JP (3) | JP3564126B2 (en) |
KR (1) | KR100339316B1 (en) |
AT (2) | ATE155810T1 (en) |
AU (1) | AU669499B2 (en) |
CA (1) | CA2122991A1 (en) |
DE (2) | DE69232728T2 (en) |
DK (2) | DK0750044T3 (en) |
ES (2) | ES2181841T3 (en) |
GR (1) | GR3025054T3 (en) |
HK (1) | HK1014033A1 (en) |
IL (1) | IL103649A0 (en) |
MX (1) | MX9206376A (en) |
MY (1) | MY119132A (en) |
NZ (1) | NZ245015A (en) |
PT (1) | PT101031B (en) |
SG (1) | SG44652A1 (en) |
WO (1) | WO1993009222A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8895050B2 (en) | 2003-08-06 | 2014-11-25 | Senomyx, Inc. | Flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof |
Families Citing this family (162)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6048729A (en) * | 1987-05-01 | 2000-04-11 | Transkaryotic Therapies, Inc. | In vivo protein production and delivery system for gene therapy |
US7094400B1 (en) * | 1987-05-01 | 2006-08-22 | Shire Human Genetic Therapies, Inc. | Transkaryotic implantation |
US5538722A (en) * | 1989-06-13 | 1996-07-23 | Stanford University | Isolation, growth, differentiation and genetic engineering of human muscle cells |
SG122763A1 (en) * | 1989-11-06 | 2006-06-29 | Cell Genesys Inc | Production of proteins using homologous recombination |
EP1375666A3 (en) | 1989-12-22 | 2007-09-26 | Applied Research Systems ARS Holding N.V. | Eukaryotic host cell line in which an endogenous gene has been activated, and uses thereof |
NZ245015A (en) * | 1991-11-05 | 1995-12-21 | Transkaryotic Therapies Inc | Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production |
US5733761A (en) | 1991-11-05 | 1998-03-31 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
US6270989B1 (en) | 1991-11-05 | 2001-08-07 | Transkaryotic Therapies, Inc. | Protein production and delivery |
US6692737B1 (en) | 1991-11-05 | 2004-02-17 | Transkaryotic Therapies, Inc. | In vivo protein production and delivery system for gene therapy |
US6063630A (en) | 1991-11-05 | 2000-05-16 | Transkaryotic Therapies, Inc. | Targeted introduction of DNA into primary or secondary cells and their use for gene therapy |
FR2686899B1 (en) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
US6670178B1 (en) | 1992-07-10 | 2003-12-30 | Transkaryotic Therapies, Inc. | In Vivo production and delivery of insulinotropin for gene therapy |
US6531124B1 (en) | 1992-07-10 | 2003-03-11 | Transkaryotic Therapies, Inc. | In vivo production and delivery of insulinotropin for gene therapy |
TW402639B (en) | 1992-12-03 | 2000-08-21 | Transkaryotic Therapies Inc | Protein production and protein delivery |
DK0695361T4 (en) * | 1993-04-21 | 2010-03-22 | Univ Edinburgh | Expression of heterologous genes according to a target expression profile |
SE9402642D0 (en) * | 1994-08-05 | 1994-08-05 | Maria Anvret | Gene Therapy |
US6419920B1 (en) | 1995-10-25 | 2002-07-16 | Trans Karyotic Therapies, Inc. | Hybrid matrix implants and explants |
US5965125A (en) * | 1995-10-25 | 1999-10-12 | Transkaryotic Therapies, Inc. | Hybrid matrix implants and explants |
US5869041A (en) * | 1996-01-12 | 1999-02-09 | The Miriam Hospital | Delivery of bioactive compounds to an organism |
EP0879279A4 (en) * | 1996-02-06 | 2000-07-12 | Lilly Co Eli | Diabetes therapy |
US6458574B1 (en) | 1996-09-12 | 2002-10-01 | Transkaryotic Therapies, Inc. | Treatment of a α-galactosidase a deficiency |
US6083725A (en) * | 1996-09-13 | 2000-07-04 | Transkaryotic Therapies, Inc. | Tranfected human cells expressing human α-galactosidase A protein |
HU230275B1 (en) * | 1996-09-13 | 2015-11-30 | Shire Human Genetic Therapies, Inc | Method for producing purified human alpha galactosidase a compositions; pharmaceutical compositions comprising said purified compositions for use in treating disorders originating from alpha galactosidase a deficiency |
GB2321642B8 (en) | 1996-10-01 | 2006-08-22 | Geron Corp | Human telomerase reverse transcriptase promoter |
US5952226A (en) * | 1996-11-05 | 1999-09-14 | Modex Therapeutiques | Hypoxia responsive EPO producing cells |
BR9808584A (en) | 1997-03-14 | 2000-05-23 | Idec Pharma Corp | Process for integrating genes at specific sites in mammalian cells via homologous recombination and vectors to obtain the same |
US6172211B1 (en) | 1997-07-11 | 2001-01-09 | Boehringer Ingelheim International Gmbh | Nucleic acid encoding tag7 polypeptide |
ATE354654T1 (en) | 1997-07-23 | 2007-03-15 | Roche Diagnostics Gmbh | IDENTIFICATION OF HUMAN CELL LINES FOR THE PRODUCTION OF HUMAN PROTEINS THROUGH ENDOGENE GENE ACTIVATION |
CN1151258C (en) * | 1997-07-23 | 2004-05-26 | 罗切诊断学有限公司 | Prodn. of erythropoietin by endogenous gene activation |
PT986644E (en) | 1997-07-23 | 2007-01-31 | Roche Diagnostics Gmbh | Production of erythropoietin by endogenous gene activation with viral promoters |
KR100622203B1 (en) | 1997-07-23 | 2006-09-07 | 로셰 디아그노스틱스 게엠베하 | Identification of human cell lines for the production of human proteins by endogenous gene activation |
US6548296B1 (en) | 1997-07-23 | 2003-04-15 | Roche Diagnostics Gmbh | Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof |
US6241701B1 (en) | 1997-08-01 | 2001-06-05 | Genetronics, Inc. | Apparatus for electroporation mediated delivery of drugs and genes |
US6055453A (en) | 1997-08-01 | 2000-04-25 | Genetronics, Inc. | Apparatus for addressing needle array electrodes for electroporation therapy |
US6216034B1 (en) | 1997-08-01 | 2001-04-10 | Genetronics, Inc. | Method of programming an array of needle electrodes for electroporation therapy of tissue |
US7316923B1 (en) | 1997-09-26 | 2008-01-08 | Athersys, Inc. | Compositions and methods for non-targeted activation of endogenous genes |
US6897066B1 (en) | 1997-09-26 | 2005-05-24 | Athersys, Inc. | Compositions and methods for non-targeted activation of endogenous genes |
ZA989497B (en) † | 1997-10-20 | 2000-04-19 | Roche Diagnostics Gmbh | Positive-negative selection in homologous recombination. |
ES2523599T3 (en) | 1997-12-03 | 2014-11-27 | Roche Diagnostics Gmbh | Erythropoietin of great specific activity |
US6541623B1 (en) | 1998-04-03 | 2003-04-01 | Hyseq, Inc. | Interleukin—1 receptor antagonist and uses thereof |
US6294655B1 (en) | 1998-04-03 | 2001-09-25 | Hyseq, Inc. | Anti-interleukin-1 receptor antagonist antibodies and uses thereof |
US6426191B1 (en) | 1998-04-03 | 2002-07-30 | Hyseq, Inc. | Assays involving an IL-1 receptor antagonist |
US6337072B1 (en) | 1998-04-03 | 2002-01-08 | Hyseq, Inc. | Interleukin-1 receptor antagonist and recombinant production thereof |
US6893838B1 (en) | 1998-04-07 | 2005-05-17 | Genetics Institute Llc | DADD, death activator death domain protein |
ATE286127T1 (en) * | 1998-04-24 | 2005-01-15 | Transkaryotic Therapies Inc | ADMINISTRATION OF THE THERAPEUTIC PROTEINS BY IMPLANTATION OF THE GENETICALLY MODIFIED CELLS INTO THE OMENTUM |
US6537806B1 (en) * | 1998-06-02 | 2003-03-25 | University Of Washington | Compositions and methods for treating diabetes |
EP1100576B1 (en) * | 1998-06-26 | 2007-08-15 | Genetronics, Inc. | Synergism of photodynamic and electropermeation effects on cell vitality as a novel cytotoxic agent |
US7922709B2 (en) | 1998-07-13 | 2011-04-12 | Genetronics, Inc. | Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation |
EP2428249B1 (en) | 1998-07-13 | 2015-10-07 | Inovio Pharmaceuticals, Inc. | Skin and muscle-targeted gene therapy by pulsed electrical field |
US6678556B1 (en) | 1998-07-13 | 2004-01-13 | Genetronics, Inc. | Electrical field therapy with reduced histopathological change in muscle |
AU761522B2 (en) | 1998-07-13 | 2003-06-05 | Genetronics, Inc. | Method and apparatus for electrically assisted topical delivery of agents for cosmetic applications |
JP2002537761A (en) * | 1998-11-24 | 2002-11-12 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | Transgenic circulating endothelial cells |
DE19857609A1 (en) | 1998-12-14 | 2000-06-15 | Hannelore Ehrenreich | Use of erythropoietin for the treatment of human cerebral ischemia |
JP4828703B2 (en) | 1999-04-28 | 2011-11-30 | ジェネティックス インスティテュート エルエルシー | Human GIL-19 / AE289 protein and polynucleotide encoding the same |
DK1054018T3 (en) | 1999-05-18 | 2009-05-18 | Dyax Corp | Fab fragment libraries and method of using them |
JP4723144B2 (en) | 1999-09-29 | 2011-07-13 | ザ ジェネラル ホスピタル コーポレイション | Polypeptide derivative of parathyroid hormone (PTH) |
MXPA02005014A (en) * | 1999-11-19 | 2003-02-27 | Transkaryotic Therapies Inc | Nucleic acid construct for optimized production of products. |
US6951839B1 (en) | 1999-11-30 | 2005-10-04 | Curis, Inc. | Methods and compositions for regulating lymphocyte activity |
US8168178B2 (en) | 1999-11-30 | 2012-05-01 | Curis, Inc. | Methods and compositions for regulating lymphocyte activity |
AU1647501A (en) | 1999-12-10 | 2001-06-18 | Cytos Biotechnology Ag | Replicon based activation of endogenous genes |
TW201006846A (en) | 2000-03-07 | 2010-02-16 | Senomyx Inc | T1R taste receptor and genes encidung same |
EP1728862A1 (en) | 2000-03-16 | 2006-12-06 | Genetica, Inc. | Methods and compositions for RNA interference |
US20030084471A1 (en) | 2000-03-16 | 2003-05-01 | David Beach | Methods and compositions for RNA interference |
US20050100991A1 (en) * | 2001-04-12 | 2005-05-12 | Human Genome Sciences, Inc. | Albumin fusion proteins |
CA2405912A1 (en) * | 2000-04-12 | 2001-10-18 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US6656700B2 (en) * | 2000-05-26 | 2003-12-02 | Amersham Plc | Isoforms of human pregnancy-associated protein-E |
US6686188B2 (en) | 2000-05-26 | 2004-02-03 | Amersham Plc | Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle |
US20040204379A1 (en) * | 2000-06-19 | 2004-10-14 | Cheng Seng H. | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
KR100407792B1 (en) * | 2000-08-02 | 2003-12-01 | 한국생명공학연구원 | Preparation method of recombinant protein by use of human glucagon-derived peptide analogue as a fusion expression partner |
EP1326630B1 (en) | 2000-09-18 | 2008-05-28 | Sanos Bioscience A/S | Use of glp-2 peptides |
US20080249016A1 (en) * | 2000-09-18 | 2008-10-09 | Sanos Bioscience A/S | Use of GLP-2 in a combination treatment for bone-related disorders |
US7371721B2 (en) * | 2000-09-18 | 2008-05-13 | Sanos Bioscience A/S | Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes |
US20070135345A1 (en) * | 2000-09-18 | 2007-06-14 | Henriksen Dennis B | Use of GLP-2 for the treatment or prevention, of bone-related disorders |
US20020123474A1 (en) * | 2000-10-04 | 2002-09-05 | Shannon Mark E. | Human GTP-Rho binding protein2 |
EP1345628B1 (en) | 2000-12-20 | 2011-04-13 | F. Hoffmann-La Roche AG | Conjugates of erythropoietin (epo) with polyethylene glycol (peg) |
PA8536201A1 (en) | 2000-12-29 | 2002-08-29 | Kenneth S Warren Inst Inc | PROTECTION AND IMPROVEMENT OF CELLS, FABRICS AND ORGANS RESPONDING TO Erythropoietin |
TW201022287A (en) | 2001-01-03 | 2010-06-16 | Senomyx Inc | T1R taste receptors and genes encoding same |
ES2328796T3 (en) | 2001-03-14 | 2009-11-18 | Myriad Genetics, Inc. | TSG101-GAG INTERACTION AND USE OF THE SAME. |
US7883856B2 (en) | 2001-04-05 | 2011-02-08 | Senomyx Inc. | Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators |
US20030143191A1 (en) * | 2001-05-25 | 2003-07-31 | Adam Bell | Chemokine beta-1 fusion proteins |
WO2003001876A2 (en) | 2001-06-26 | 2003-01-09 | Senomyx, Inc. | T1r hetero-oligomeric taste receptors and cell lines that express said receptors and use thereof for identification of taste compounds |
US20040204669A1 (en) * | 2001-07-05 | 2004-10-14 | Hofmann Gunter A. | Apparatus for electroporation mediated delivery for drugs and genes |
IL159640A0 (en) | 2001-07-10 | 2004-06-01 | Senomyx Inc | Use of specific t2r taste receptors to identify compounds that block bitter taste |
CN1363654A (en) * | 2001-07-19 | 2002-08-14 | 上海华谊生物技术有限公司 | Genetically engineered bacteria and process for preparing insulinotropic hormone secretion peptide GLP-1 (7-36) |
CA2450073C (en) * | 2001-07-25 | 2017-08-29 | Biomarin Pharmaceutical Inc. | Compositions and methods for modulating blood-brain barrier transport |
US6867189B2 (en) * | 2001-07-26 | 2005-03-15 | Genset S.A. | Use of adipsin/complement factor D in the treatment of metabolic related disorders |
US6642003B2 (en) | 2001-08-02 | 2003-11-04 | Cedars-Sinai Medical Center | Human glucose-dependent insulin-secreting cell line |
US20040078837A1 (en) * | 2001-08-02 | 2004-04-22 | Shannon Mark E. | Four human zinc-finger-containing proteins: MDZ3, MDZ4, MDZ7 and MDZ12 |
US20040143104A1 (en) * | 2001-08-08 | 2004-07-22 | Wadsworth Samuel C. | Methods of treating diabetes and other blood sugar disorders |
EP1446171A1 (en) * | 2001-11-16 | 2004-08-18 | Children's Medical Center Corporation | Augmentation of organ function |
ES2545090T3 (en) * | 2001-12-21 | 2015-09-08 | Human Genome Sciences, Inc. | Albumin and GCSF fusion proteins |
AU2002364587A1 (en) * | 2001-12-21 | 2003-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
JP2005532033A (en) * | 2002-01-17 | 2005-10-27 | ロンザ・バイオロジクス・ピーエルシー | Glutamine auxotrophic human cells with the ability to produce proteins and have the ability to grow in glutamine-free media |
EP1585386A4 (en) | 2002-02-20 | 2009-09-02 | American Integrated Biolog Inc | Transgenic production in saliva |
US7141240B2 (en) * | 2002-03-12 | 2006-11-28 | Cedars-Sinai Medical Center | Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1 |
BRPI0309665B8 (en) | 2002-04-25 | 2021-05-25 | Transkaryotic Therapies Inc | method for analyzing an alpha-galactosidase preparation a |
US7374930B2 (en) * | 2002-05-21 | 2008-05-20 | Expression Genetics, Inc. | GLP-1 gene delivery for the treatment of type 2 diabetes |
US7459435B2 (en) | 2002-08-29 | 2008-12-02 | Hoffmann-La Roche Inc. | Treatment of disturbances of iron distribution |
US7611700B2 (en) * | 2002-09-09 | 2009-11-03 | Hanall Pharmaceuticals, Co., Ltd. | Protease resistant modified interferon alpha polypeptides |
US7459436B2 (en) | 2002-11-22 | 2008-12-02 | Hoffmann-La Roche Inc. | Treatment of disturbances of iron distribution |
JP2006517101A (en) * | 2003-01-13 | 2006-07-20 | エス. ラオ、マヘンドラ | Sustained expression of candidate molecules in proliferating stem and progenitor cells to deliver therapeutic products |
US20050048041A1 (en) * | 2003-01-13 | 2005-03-03 | Rao Mahendra S. | Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products |
WO2004064785A2 (en) | 2003-01-14 | 2004-08-05 | Dana Farber Cancer Institute | Cancer therapy sensitizer |
US7595306B2 (en) * | 2003-06-09 | 2009-09-29 | Alnylam Pharmaceuticals Inc | Method of treating neurodegenerative disease |
CA2549486C (en) * | 2003-12-19 | 2015-04-14 | F. Hoffmann-La Roche Ag | Use of erythropoietin in the treatment of disturbances of iron distribution in chronic inflammatory intestinal diseases |
EP1789070B1 (en) | 2004-08-03 | 2012-10-24 | Biogen Idec MA Inc. | Taj in neuronal function |
EP2298897B1 (en) | 2004-09-02 | 2013-08-14 | Yale University | Regulation of oncogenes by microRNAs |
EP2932982B1 (en) | 2005-05-17 | 2018-10-03 | Amicus Therapeutics, Inc. | A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives |
US8354384B2 (en) | 2005-06-23 | 2013-01-15 | Yale University | Anti-aging micrornas |
EP1931384A4 (en) | 2005-09-09 | 2010-03-10 | Univ Johns Hopkins | Manipulation of regulatory t cell and dc function by targeting neuritin gene using antibodies, agonists and antagonists |
JP5342878B2 (en) | 2005-10-20 | 2013-11-13 | セノミクス・インコーポレーテッド | Chimeric human sweetness-umami and umami-sweet taste receptors |
US7749730B2 (en) | 2005-11-03 | 2010-07-06 | Redpoint Bio Corporation | High throughput screening assay for the TRPM5 ion channel |
DE102006004008A1 (en) | 2006-01-27 | 2007-08-02 | Hannelore Prof. Dr. Dr. Ehrenreich | Treating or preventing multiple sclerosis comprises administering erythropoietin for periods separated by intervals in which no erythropoietin is administered |
US8129334B2 (en) | 2006-03-31 | 2012-03-06 | The Regents Of The University Of California | Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory |
ES2640453T3 (en) | 2006-04-21 | 2017-11-03 | Senomyx, Inc. | Processes for preparing solid flavoring compositions |
JP2007325571A (en) * | 2006-06-09 | 2007-12-20 | Toto Ltd | Method for producing protein using recombinant mammalian cell |
WO2007150069A2 (en) | 2006-06-23 | 2007-12-27 | Myriad Genetics, Inc. | Dpyd gene variants and use thereof |
US7674594B2 (en) | 2006-07-27 | 2010-03-09 | Redpoint Bio Corporation | Screening assay for inhibitors of TRPA1 activation by a lower alkyl phenol |
EP2120998B1 (en) | 2006-11-28 | 2013-08-07 | HanAll Biopharma Co., Ltd. | Modified erythropoietin polypeptides and uses thereof for treatment |
US9029383B2 (en) | 2007-05-11 | 2015-05-12 | The Trustees Of The University Of Pennsylvania | Methods of treatment of skin ulcers |
CN101986785A (en) | 2007-05-11 | 2011-03-16 | 托马斯杰弗逊大学 | Methods of treatment and prevention of neurodegenerative diseases and disorders |
JP2010528658A (en) * | 2007-06-08 | 2010-08-26 | ウェイク・フォレスト・ユニヴァーシティ・ヘルス・サイエンシズ | Selective cell therapy for the treatment of renal failure |
US9580688B2 (en) * | 2007-06-08 | 2017-02-28 | Wake Forest University Health Sciences | Kidney structures and methods of forming the same |
EP2006388A1 (en) * | 2007-06-19 | 2008-12-24 | Helmholtz-Zentrum für Infektionsforschung GmbH | Nucleic acid constructs for deactivation and conditional mutagenesis of genes |
AR067536A1 (en) | 2007-07-17 | 2009-10-14 | Hoffmann La Roche | METHOD FOR OBTAINING A MONO-PEGILATED ERYTHROPOYETIN IN A SUBSTANTIALLY HOMOGENOUS FORM |
AR067537A1 (en) | 2007-07-17 | 2009-10-14 | Hoffmann La Roche | PURIFIED POLYPEPTIDES PURIFICATION |
WO2009010107A1 (en) | 2007-07-19 | 2009-01-22 | Hannelore Ehrenreich | Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis |
JP5711966B2 (en) | 2007-08-01 | 2015-05-07 | ザ ジェネラル ホスピタル コーポレイション | Screening methods using G protein-coupled receptors and related compositions |
JP4997253B2 (en) * | 2007-08-10 | 2012-08-08 | Toto株式会社 | Recombinant mammalian cell, method for producing recombinant mammalian cell, and method for producing target protein |
CA2982520A1 (en) | 2007-08-21 | 2009-02-26 | Senomyx, Inc. | Identification of human t2r receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in compositions and use thereof |
WO2009079399A2 (en) * | 2007-12-14 | 2009-06-25 | Alnylam Pharmaceuticals, Inc. | Method of treating neurodegenerative disease |
CN105274072A (en) | 2008-01-18 | 2016-01-27 | 生物马林药物股份有限公司 | Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof |
US20090291073A1 (en) * | 2008-05-20 | 2009-11-26 | Ward Keith W | Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same |
BRPI0919403A2 (en) | 2008-09-26 | 2017-09-26 | Ambrx Inc | modified animal erythropoietin polypeptides and their uses |
US8110185B2 (en) | 2008-10-03 | 2012-02-07 | St. Michael's Hospital | Method for preventing and treating cardiovascular diseases with BRCA1 |
EP2358375B1 (en) | 2008-11-12 | 2013-07-24 | Tengion, Inc. | Isolated renal cells and uses thereof |
WO2010057013A1 (en) * | 2008-11-14 | 2010-05-20 | Wake Forest University Health Sciences | Selective cell therapy for the treatment of renal failure |
US20100178641A1 (en) * | 2009-01-12 | 2010-07-15 | Franklin David Damon | Apparel fastening learning apparatus |
US8211655B2 (en) | 2009-02-12 | 2012-07-03 | Discoverx Corporation | Wild-type receptor assays |
US20110300205A1 (en) | 2009-07-06 | 2011-12-08 | Novartis Ag | Self replicating rna molecules and uses thereof |
CN102712688B (en) | 2009-09-23 | 2015-06-24 | 通益制药有限公司 | Process for the purification of recombinant human erythropoietin (EPO), EPO thus purified and pharmaceutical compositions comprising same |
KR101900078B1 (en) | 2010-05-13 | 2018-09-18 | 더 제너럴 하스피탈 코포레이션 | Parathyroid hormone analogs and uses thereof |
AR082319A1 (en) | 2010-07-22 | 2012-11-28 | Biomarin Pharm Inc | PRODUCTION OF A HIGHLY ACTIVE PHOSPHORILED HUMAN N-ACETILGALACTOSAMINE-6-SULPHATASE AND ITS USES |
EP2616101B1 (en) | 2010-09-14 | 2014-07-09 | F.Hoffmann-La Roche Ag | Method for purifying pegylated erythropoietin |
KR102056324B1 (en) | 2010-11-10 | 2019-12-16 | 인리젠 | Injectable formulations for organ augmentation |
AU2011336467A1 (en) | 2010-12-01 | 2013-07-04 | Spinal Modulation, Inc. | Agent delivery systems for selective neuromodulation |
US8759313B2 (en) | 2011-08-03 | 2014-06-24 | The Charlotte-Mecklenburg Hospital Authority | Treatment of fibrosis using microRNA 19b |
US20140227293A1 (en) | 2011-06-30 | 2014-08-14 | Trustees Of Boston University | Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1) |
CA2841047A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic compositions and uses thereof |
ES2656050T3 (en) | 2011-07-06 | 2018-02-22 | Glaxosmithkline Biologicals Sa | Immunogenic combination compositions and uses thereof |
JP2015522580A (en) | 2012-07-06 | 2015-08-06 | ノバルティス アーゲー | Immunological compositions and uses thereof |
US10066001B2 (en) | 2013-03-15 | 2018-09-04 | Apotex Inc. | Enhanced liquid formulation stability of erythropoietin alpha through purification processing |
CA2915948A1 (en) | 2013-08-20 | 2015-02-26 | Lek Pharmaceuticals D.D. | Cell culture medium and process for controlling a-amidation and/or c-terminal amino acid cleavage of polypeptides |
EP3194581A4 (en) | 2014-09-15 | 2018-04-25 | Children's Medical Center Corporation | Methods and compositions to increase somatic cell nuclear transfer (scnt) efficiency by removing histone h3-lysine trimethylation |
MA40871A (en) | 2014-10-29 | 2017-09-05 | Novartis Ag | DIRECT EXPRESSION OF ANTIBODIES |
PL3484911T3 (en) | 2016-07-15 | 2021-03-08 | F. Hoffmann-La Roche Ag | Method for purifying pegylated erythropoietin |
US11123372B2 (en) | 2016-07-29 | 2021-09-21 | Prokidney | Bioactive renal cells for the treatment of chronic kidney disease |
SG11202005952TA (en) | 2017-12-29 | 2020-07-29 | Hoffmann La Roche | Process for providing pegylated protein composition |
EP3731871B1 (en) | 2017-12-29 | 2023-10-04 | F. Hoffmann-La Roche AG | Process for providing pegylated protein composition |
SG11202006140TA (en) | 2017-12-29 | 2020-07-29 | Hoffmann La Roche | Process for providing pegylated protein composition |
IL296125A (en) * | 2020-03-04 | 2022-11-01 | Metcela Inc | Fibroblast having enhanced erythropoietin production ability |
WO2022159414A1 (en) | 2021-01-22 | 2022-07-28 | University Of Rochester | Erythropoietin for gastroinfestinal dysfunction |
Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2159172A (en) * | 1984-05-24 | 1985-11-27 | Damon Biotech Inc | Production of antibodies |
WO1987000201A1 (en) * | 1985-07-05 | 1987-01-15 | Whitehead Institute For Biomedical Research | Epithelial cells expressing foreign genetic material |
EP0236059A2 (en) * | 1986-02-27 | 1987-09-09 | Snow Brand Milk Products Co. Ltd. | Preparation of erythropoietin-producing cells and production process of erythropoietin using same |
WO1988000239A1 (en) * | 1986-06-30 | 1988-01-14 | Pharmaceutical Proteins Ltd | Peptide production |
EP0255231A1 (en) * | 1986-06-27 | 1988-02-03 | The Board Of Regents Of The University Of Washington | Human erythropoietin gene: high level expression in stably transfected mammalian cells |
WO1988008306A1 (en) * | 1987-05-01 | 1988-11-03 | The General Hospital Corporation | Transkaryotic implantation |
WO1989001517A1 (en) * | 1987-08-07 | 1989-02-23 | Medical Res Council | Vector for integration site independent gene expression in mammalian host cells |
WO1990011354A1 (en) * | 1989-03-20 | 1990-10-04 | Institut Pasteur | Process for the specific replacement of a copy of a gene present in the receiver genome via the integration of a gene |
WO1991009955A1 (en) * | 1989-12-22 | 1991-07-11 | Applied Research Systems Ars Holding N.V. | Endogenous gene expression modification with regulatory element |
WO1991013151A1 (en) * | 1990-02-22 | 1991-09-05 | Biogen, Inc. | Improved expression of polypeptides |
EP0452894A2 (en) * | 1990-04-19 | 1991-10-23 | Consiglio Nazionale Delle Ricerche | Human cells for the high expression of genes inserted in episomal recombinant DNA, their preparation and their use |
WO1991019796A1 (en) * | 1990-06-12 | 1991-12-26 | Baylor College Of Medicine | Method for homologous recombination in animal and plant cells |
WO1992003917A1 (en) * | 1990-08-29 | 1992-03-19 | Genpharm International | Homologous recombination in mammalian cells |
WO1992008796A1 (en) * | 1990-11-13 | 1992-05-29 | Immunex Corporation | Bifunctional selectable fusion genes |
WO1992019255A1 (en) * | 1991-05-06 | 1992-11-12 | Cell Genesys, Inc. | Gene manipulation and expression using genomic elements |
WO1992020808A1 (en) * | 1991-05-15 | 1992-11-26 | Cell Genesys, Inc. | Genomic modifications with homologous dna targeting |
WO1993004169A1 (en) * | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4396601A (en) * | 1980-03-26 | 1983-08-02 | The Regents Of The University Of Calif. | Gene transfer in intact mammals |
US4497796A (en) * | 1980-03-26 | 1985-02-05 | The Regents Of The University Of California | Gene transfer in intact mammals |
DE3176404D1 (en) * | 1980-04-22 | 1987-10-08 | Pasteur Institut | Vaccine against viral hepatitis b, method and transformed eucaryotic cells for the preparation of this vaccine |
NZ210501A (en) * | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
CA1215922A (en) * | 1984-05-25 | 1986-12-30 | Connaught Laboratories Limited | Microencapsulation of living tissue and cells |
WO1986004920A1 (en) * | 1985-02-13 | 1986-08-28 | Biotechnology Research Partners, Limited | Human metallothionein-ii promoter in mammalian expression system |
US4980286A (en) * | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
US5118666A (en) * | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
US5219740A (en) * | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
US5175255A (en) * | 1987-03-23 | 1992-12-29 | Amgen Inc. | Methods for purification of platelet-derived growth factor |
US6048729A (en) * | 1987-05-01 | 2000-04-11 | Transkaryotic Therapies, Inc. | In vivo protein production and delivery system for gene therapy |
US5166059A (en) * | 1987-06-16 | 1992-11-24 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy using gene fusions for genetic or acquired disorders |
AU613063B2 (en) * | 1987-07-06 | 1991-07-25 | Komatsu Zenoah Kabushiki Kaisha | Fuel supply system |
DE3852823T2 (en) * | 1987-09-11 | 1995-05-24 | Whitehead Biomedical Inst | TRANSDUCTION-CHANGED FIBROBLASTS AND THEIR USE. |
US4892538A (en) * | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
US4890286A (en) * | 1987-12-11 | 1989-12-26 | Sanyo Electric Co., Ltd. | Method and apparatus for decoding error correcting code |
DE3851153T2 (en) * | 1987-12-11 | 1995-01-05 | Whitehead Biomedical Inst | GENETIC MODIFICATION OF ENDOTHELIAL CELLS. |
DE3802640A1 (en) * | 1988-01-29 | 1989-08-03 | Roehm Gmbh | HAIR-RESERVED AASIS PROCEDURE |
EP0732397A3 (en) * | 1988-02-05 | 1996-10-23 | Whitehead Institute For Biomedical Research | Modified hepatocytes and uses therefor |
JPH04507041A (en) * | 1988-12-13 | 1992-12-10 | アメリカ合衆国 | Endothelial cells modified by genetic engineering and methods for their use |
US5082670A (en) * | 1988-12-15 | 1992-01-21 | The Regents Of The University Of California | Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system |
GB8907700D0 (en) * | 1989-04-05 | 1989-05-17 | Fine Organics Ltd | Preparation of substituted ethenes |
GB8909218D0 (en) * | 1989-04-22 | 1989-06-07 | Medical Res Council | Improvements in or relating to enhancers |
CA2058955A1 (en) * | 1989-06-13 | 1990-12-14 | Helen Blau | Isolation growth and differentiation of human muscle cells |
US5399346A (en) * | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
US5464764A (en) * | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
SG122763A1 (en) * | 1989-11-06 | 2006-06-29 | Cell Genesys Inc | Production of proteins using homologous recombination |
US5272071A (en) * | 1989-12-22 | 1993-12-21 | Applied Research Systems Ars Holding N.V. | Method for the modification of the expression characteristics of an endogenous gene of a given cell line |
EP0556345B2 (en) * | 1990-10-31 | 2005-10-12 | Cell Genesys, Inc. | Retroviral vectors useful for gene therapy |
AU9179591A (en) * | 1990-12-26 | 1992-08-17 | Howard Hughes Medical Center | Modified hepatocytes and uses therefor |
WO1992015676A1 (en) * | 1991-03-08 | 1992-09-17 | The Salk Institute For Biological Studies | Somatic cell gene therapy |
US6063630A (en) * | 1991-11-05 | 2000-05-16 | Transkaryotic Therapies, Inc. | Targeted introduction of DNA into primary or secondary cells and their use for gene therapy |
US6054288A (en) * | 1991-11-05 | 2000-04-25 | Transkaryotic Therapies, Inc. | In vivo protein production and delivery system for gene therapy |
NZ245015A (en) * | 1991-11-05 | 1995-12-21 | Transkaryotic Therapies Inc | Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production |
US6670178B1 (en) * | 1992-07-10 | 2003-12-30 | Transkaryotic Therapies, Inc. | In Vivo production and delivery of insulinotropin for gene therapy |
US6531124B1 (en) * | 1992-07-10 | 2003-03-11 | Transkaryotic Therapies, Inc. | In vivo production and delivery of insulinotropin for gene therapy |
KR960037062A (en) * | 1996-08-02 | 1996-11-19 | 오동덕 | Manufacturing method of therapeutic agent for purulent skin disease |
-
1992
- 1992-11-04 NZ NZ245015A patent/NZ245015A/en not_active IP Right Cessation
- 1992-11-04 PT PT101031A patent/PT101031B/en not_active IP Right Cessation
- 1992-11-05 CA CA002122991A patent/CA2122991A1/en not_active Abandoned
- 1992-11-05 AT AT92924367T patent/ATE155810T1/en not_active IP Right Cessation
- 1992-11-05 WO PCT/US1992/009627 patent/WO1993009222A2/en not_active Application Discontinuation
- 1992-11-05 ES ES96202037T patent/ES2181841T3/en not_active Expired - Lifetime
- 1992-11-05 EP EP01204619A patent/EP1221477A3/en not_active Withdrawn
- 1992-11-05 DE DE69232728T patent/DE69232728T2/en not_active Expired - Fee Related
- 1992-11-05 AT AT96202037T patent/ATE221917T1/en not_active IP Right Cessation
- 1992-11-05 MY MYPI92002007A patent/MY119132A/en unknown
- 1992-11-05 EP EP92924367A patent/EP0649464B1/en not_active Revoked
- 1992-11-05 AU AU30698/92A patent/AU669499B2/en not_active Ceased
- 1992-11-05 IL IL103649A patent/IL103649A0/en not_active IP Right Cessation
- 1992-11-05 JP JP50876793A patent/JP3564126B2/en not_active Expired - Fee Related
- 1992-11-05 DK DK96202037T patent/DK0750044T3/en active
- 1992-11-05 EP EP96202037A patent/EP0750044B1/en not_active Expired - Lifetime
- 1992-11-05 MX MX9206376A patent/MX9206376A/en active IP Right Grant
- 1992-11-05 SG SG1996005101A patent/SG44652A1/en unknown
- 1992-11-05 ES ES92924367T patent/ES2106891T3/en not_active Expired - Lifetime
- 1992-11-05 DE DE69221168T patent/DE69221168T2/en not_active Revoked
- 1992-11-05 DK DK92924367.3T patent/DK0649464T3/en active
-
1994
- 1994-05-04 KR KR10-1994-0701527A patent/KR100339316B1/ko not_active IP Right Cessation
- 1994-11-04 US US08/334,455 patent/US5994127A/en not_active Expired - Lifetime
-
1995
- 1995-05-22 US US08/446,909 patent/US6048524A/en not_active Expired - Lifetime
- 1995-05-22 US US08/446,911 patent/US6048724A/en not_active Expired - Lifetime
-
1997
- 1997-10-15 GR GR970402700T patent/GR3025054T3/en unknown
-
1998
- 1998-12-24 HK HK98115412A patent/HK1014033A1/en not_active IP Right Cessation
-
1999
- 1999-06-08 US US09/328,130 patent/US6846676B2/en not_active Expired - Fee Related
- 1999-10-19 US US09/420,861 patent/US6355241B1/en not_active Expired - Lifetime
-
2002
- 2002-12-11 JP JP2002359926A patent/JP3733110B2/en not_active Expired - Fee Related
-
2004
- 2004-07-07 US US10/885,899 patent/US7410799B2/en not_active Expired - Lifetime
- 2004-07-22 JP JP2004214021A patent/JP2005046147A/en active Pending
-
2008
- 2008-06-24 US US12/145,324 patent/US20100143314A1/en not_active Abandoned
Patent Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2159172A (en) * | 1984-05-24 | 1985-11-27 | Damon Biotech Inc | Production of antibodies |
WO1987000201A1 (en) * | 1985-07-05 | 1987-01-15 | Whitehead Institute For Biomedical Research | Epithelial cells expressing foreign genetic material |
EP0236059A2 (en) * | 1986-02-27 | 1987-09-09 | Snow Brand Milk Products Co. Ltd. | Preparation of erythropoietin-producing cells and production process of erythropoietin using same |
EP0255231A1 (en) * | 1986-06-27 | 1988-02-03 | The Board Of Regents Of The University Of Washington | Human erythropoietin gene: high level expression in stably transfected mammalian cells |
WO1988000239A1 (en) * | 1986-06-30 | 1988-01-14 | Pharmaceutical Proteins Ltd | Peptide production |
WO1988008306A1 (en) * | 1987-05-01 | 1988-11-03 | The General Hospital Corporation | Transkaryotic implantation |
WO1989001517A1 (en) * | 1987-08-07 | 1989-02-23 | Medical Res Council | Vector for integration site independent gene expression in mammalian host cells |
WO1990011354A1 (en) * | 1989-03-20 | 1990-10-04 | Institut Pasteur | Process for the specific replacement of a copy of a gene present in the receiver genome via the integration of a gene |
WO1991009955A1 (en) * | 1989-12-22 | 1991-07-11 | Applied Research Systems Ars Holding N.V. | Endogenous gene expression modification with regulatory element |
WO1991013151A1 (en) * | 1990-02-22 | 1991-09-05 | Biogen, Inc. | Improved expression of polypeptides |
EP0452894A2 (en) * | 1990-04-19 | 1991-10-23 | Consiglio Nazionale Delle Ricerche | Human cells for the high expression of genes inserted in episomal recombinant DNA, their preparation and their use |
WO1991019796A1 (en) * | 1990-06-12 | 1991-12-26 | Baylor College Of Medicine | Method for homologous recombination in animal and plant cells |
WO1992003917A1 (en) * | 1990-08-29 | 1992-03-19 | Genpharm International | Homologous recombination in mammalian cells |
WO1992008796A1 (en) * | 1990-11-13 | 1992-05-29 | Immunex Corporation | Bifunctional selectable fusion genes |
WO1992019255A1 (en) * | 1991-05-06 | 1992-11-12 | Cell Genesys, Inc. | Gene manipulation and expression using genomic elements |
WO1992020808A1 (en) * | 1991-05-15 | 1992-11-26 | Cell Genesys, Inc. | Genomic modifications with homologous dna targeting |
WO1993004169A1 (en) * | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
Non-Patent Citations (27)
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8895050B2 (en) | 2003-08-06 | 2014-11-25 | Senomyx, Inc. | Flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100339316B1 (en) | ||
MY140230A (en) | Activating expression of an amplifying endogenous gene by homologous recombination | |
JP4562915B2 (en) | Overexpression of the desired protein in eukaryotic cells mediated by overexpression of cyclin D1 | |
US5354674A (en) | Method of gene transfer using retrotransposons | |
CN101622353B (en) | Improvement of protein production | |
MX9605542A (en) | Dna construct for effecting homologous recombination and uses thereof. | |
NL930127I1 (en) | Formation of a multi-active granulocyte colony stimulating factor | |
WO1999064565A3 (en) | Regulation of hematopoietic stem cell differentiation by the use of human mesenchymal stem cells | |
Bao et al. | Secretion of human proteins from yeast: stimulation by duplication of polyubiquitin and protein disulfide isomerase genes in Kluyveromyces lactis | |
CN103923942B (en) | A kind ofly express the reversion of pig Telomerase enzyme transposon vector and construction process thereof and setting up the application in pig immortalized cell line | |
JO1694B1 (en) | New chemical products | |
CN104342454A (en) | Expression vector for producing protein derived from foreign gene in large quantity using animal cells, and use thereof | |
JP6469371B2 (en) | A method for expressing a plurality of foreign genes in an embryoid body composed of induced pluripotent stem cells (iPS cells) | |
Li et al. | Retrovectors packaged in CHO cells to generate GLP-1-Fc stable expression CHO cell lines | |
Lampela et al. | Efficient transfection of novel bovine papillomavirus 1 expression plasmids | |
Monaco | Optimizing gene expression in mammalian cells | |
Chau et al. | Gene transfer into retinoblastoma cells | |
Le Blay et al. | Efficient transient gene expression in neurosphere with jetMESSENGER™ mRNA Transfection Reagent | |
CN103509754A (en) | On-HIV-1 LTR cis-element mutant eukaryotic cell system, and preparation method and application thereof | |
Girard et al. | Scalable, Serum-Free, High Efficiency Transfection of CHO Cells Using an Economical DNA Transfer Vehicle | |
Pavlin et al. | Optimization of electrotransfer parameters for siRNA delivery into primary human myoblasts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA JP KR |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA JP KR |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2122991 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1992924367 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1992924367 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 1996 737264 Country of ref document: US Date of ref document: 19961126 Kind code of ref document: A |
|
WWG | Wipo information: grant in national office |
Ref document number: 1992924367 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1992924367 Country of ref document: EP |